Contribute
España
Italia
대한민국
日本
Français
Benzinga
Research
My Stocks
Tools
Free Benzinga Pro Trial
SPY
765.410.07%
QQQ
717.380.14%
BTC/USD
78885.350.551%
DIA
527.560.09%
GLD
398.850.22%
TLT
82.140.07%

enGene Therapeutics Inc (ENGN) Stock Price, Quote, News & History

ENGNNASDAQ
Trade with Public
Trade with Public
$1.92
0.15.49%
At close: Sep 8, 5:00 PM EST
$1.92
N/A
After Hours: 4:38 PM EST
Earnings: Q3 2026 Earnings were released on Tue Sep 8th, before the market open
OverviewNewsEarnings ForecastEventsPrice TargetsFinancialsSentimentOwnershipCompareOptionsStock Report

enGene Therapeutics (ENGN) Stock Price, Quote, News & History | Benzinga

Key Statistics

Open
$1.82
Close
$1.92
Volume / Avg.
1.51M / 868.96K
Day Range
$1.78 - $1.94
52 Wk Range
1.40 - 12.25
Market Cap
$128.62M
P/E Ratio
-
Dividend Yield
-
Exchange
NASDAQ
RSI
57
Short Interest
2.75%
Days to Cover
2.2

Recent enGene Therapeutics Inc. News

This Intuit Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For Thursday

Wall Street analysts updated ratings for CURB, INTU, ENGN. See their outlooks and targets at Benzinga's analyst ratings page.
Avi Kapoor

W.P. Carey To Rally Around 10%? Here Are 10 Top Analyst Forecasts For Tuesday

Top analysts changed ratings on top names, including Sunrun, enGene Therapeutics, Camp4 Therapeutics, PennyMac Financial, Dave & Buster's, Neumora Therapeutics, Extra Space Storage, & W. P. Carey. See full list here.
Avi Kapoor

Why Is enGene Therapeutics Stock Falling Friday?

enGene stock sinks after Phase 2 bladder cancer trial shows durability concerns. Analysts slash price forecasts as the sell-off intensifies.
Kaustubh Bagalkote

Dow Dips 350 Points; US Foods Posts Downbeat Earnings

Dow falls over 100 points, S&P 500 and NASDAQ also down. Tech sector up, energy stocks down. US Foods reports lower Q1 earnings and sales. Agilon Health, Aaon, and Rackspace Technology see gains while Entrada, Fastly, and enGene Therapeutics decline. Euro zone and Asian markets mixed.
Avi Kapoor

US Stocks Mixed; Dow Falls Over 100 Points

US stocks higher Thursday morning, Dow down 0.28%, Nasdaq up 0.50%, S&P 500 up 0.07%. Tech sector up 1.1%, energy sector down 2.8%. McDonald's reports strong earnings and sales.
Avi Kapoor

Financials

Quarterly
Annual
Name
Revenue
Change
Gross
Change
EBITDA
Change
EBIT
Change
Earnings
Change

Cash Flows

Operating Cash Flow (TTM)
-110.00M
Investing Cash Flow (TTM)
-60.78M
Financing Cash Flow (TTM)
143.06M
Free Cash Flow (TTM)
-111.39M
Capital Expenditure (TTM)
-1.39M
Net Change in Cash (TTM)
-27.72M

Analyst Trends and Forecast

1
Mar
1
Apr
1
5
May
1
1
Jun
1
Sep
Buy
Hold
Sell
Strong Sell

Analyst Rating and Forecast

12345
3.9
Buy
Strong Buy
Buy
Hold
Sell
Strong Sell

Valuation Metrics

Enterprise Value
-$103.19M
PE Ratio (TTM)
-
PE Ratio (FWD)
-
PEG Ratio (TTM)
-
PS Ratio (TTM)
-
PB Ratio (TTM)
0.48
Earnings Yield % (TTM)
-120.11%
Earnings Yield % (FWD)
-95.59%
EV / EBITDA (TTM)
-
Price / EBITDA (TTM)
-
Price / Free Cash Flow (TTM)
-
Book Value / Share
$3.81

Company Debt

Total Debt
$25.10M
LT Debt
$24.91M
LT Debt Issuance (TTM)
$25.00M
LT Debt Repayment (TTM)
-$23.75M
Total Cash
$29.83M
Debt to Equity
0.13
Issuance of Debt (TTM)
$1.25M
Repayment of Debt (TTM)
-$23.75M

Key Statistics

Open
$1.82
Close
$1.92
Volume / Avg.
1.51M / 868.96K
Day Range
$1.78 - $1.94
52 Wk Range
1.40 - 12.25
Market Cap
$128.62M
P/E Ratio
-
Dividend Yield
-
Exchange
NASDAQ
RSI
57
Short Interest
2.75%
Days to Cover
2.2

About

Sector
Health Care
Industry
Biotechnology
enGene Therapeutics Inc is a clinical-stage biotechnology company mainstreaming gene therapy through the delivery of therapeutics to mucosal tissues and other organs, to create new ways to address diseases with high clinical needs. Its pioneering pro...
Show More
Edge Rankings

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score

Compare

EPS worse than industry
Earnings Per Share
EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

FAQ

Q

How do I buy enGene Therapeutics (ENGN) stock?

A

You can purchase shares of enGene Therapeutics (NASDAQ:ENGN) through any online brokerage.

View our list of the best stock brokerages

Q

Who are enGene Therapeutics (ENGN) competitors?

Q

What is the forecast, or price target, for enGene Therapeutics (ENGN) stock?

A

enGene Therapeutics has a consensus price target of $18.04.

Q

What is the current price for enGene Therapeutics (ENGN)?

A

The stock price for enGene Therapeutics (NASDAQ: ENGN) is $1.92 last updated September 8, 2026 at 4:38 PM EDT.

Q

Does enGene Therapeutics (ENGN) pay a dividend?

A

There are no upcoming dividends for enGene Therapeutics.

Q

When is enGene Therapeutics (NASDAQ:ENGN) reporting earnings?

A

enGene Therapeutics does not have any upcoming earnings scheduled.

Q

Is enGene Therapeutics (ENGN) going to split?

A

There is no upcoming split for enGene Therapeutics.

Q

What sector and industry does enGene Therapeutics (ENGN) operate in?

A

enGene Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.

Data & APIs: Benzinga APIs · Stock News API · Analyst Ratings API · Company Logo API

Market data provided by Benzinga APIs

Connect With Us
instagramlinkedinyoutubeblueskymastodon
About Benzinga
Market Resources
Trading Tools & Education
Ring the Bell
© 2026 Benzinga | All Rights Reserved